Compare Novartis with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs STRIDES PHARMA SCIENCE - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS STRIDES PHARMA SCIENCE NOVARTIS/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 674.9 4.9 13,891.0% View Chart
P/BV x 20.3 0.7 2,711.4% View Chart
Dividend Yield % 2.2 0.6 335.3%  

Financials

 NOVARTIS   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    NOVARTIS
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
NOVARTIS/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs9801,147 85.4%   
Low Rs600642 93.5%   
Sales per share (Unadj.) Rs198.7317.2 62.6%  
Earnings per share (Unadj.) Rs21.07.8 267.3%  
Cash flow per share (Unadj.) Rs22.325.1 88.8%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.30.2 566.1%  
Book value per share (Unadj.) Rs307.5274.3 112.1%  
Shares outstanding (eoy) m24.6989.50 27.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.02.8 141.0%   
Avg P/E ratio x37.7114.0 33.0%  
P/CF ratio (eoy) x35.535.7 99.4%  
Price / Book Value ratio x2.63.3 78.8%  
Dividend payout %47.725.5 187.1%   
Avg Mkt Cap Rs m19,50880,058 24.4%   
No. of employees `0000.62.5 23.2%   
Total wages/salary Rs m1,1714,341 27.0%   
Avg. sales/employee Rs Th8,445.411,325.8 74.6%   
Avg. wages/employee Rs Th2,015.71,731.4 116.4%   
Avg. net profit/employee Rs Th891.0280.1 318.2%   
INCOME DATA
Net Sales Rs m4,90728,394 17.3%  
Other income Rs m783941 83.2%   
Total revenues Rs m5,68929,334 19.4%   
Gross profit Rs m1233,965 3.1%  
Depreciation Rs m321,540 2.1%   
Interest Rs m161,962 0.8%   
Profit before tax Rs m8581,403 61.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m34097 349.4%   
Profit after tax Rs m518702 73.7%  
Gross profit margin %2.514.0 17.9%  
Effective tax rate %39.66.9 571.7%   
Net profit margin %10.62.5 426.7%  
BALANCE SHEET DATA
Current assets Rs m8,05524,836 32.4%   
Current liabilities Rs m1,85018,993 9.7%   
Net working cap to sales %126.420.6 614.5%  
Current ratio x4.41.3 332.9%  
Inventory Days Days4571 63.4%  
Debtors Days Days34113 29.9%  
Net fixed assets Rs m15034,289 0.4%   
Share capital Rs m123895 13.8%   
"Free" reserves Rs m7,46923,651 31.6%   
Net worth Rs m7,59224,546 30.9%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m9,82465,437 15.0%  
Interest coverage x54.91.7 3,203.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.4 115.1%   
Return on assets %5.44.1 133.4%  
Return on equity %6.82.9 238.4%  
Return on capital %11.56.9 166.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5815,697 0.4%   
Fx outflow Rs m1,326735 180.4%   
Net fx Rs m-1,26914,962 -8.5%   
CASH FLOW
From Operations Rs m-1,9431,871 -103.9%  
From Investments Rs m2,7425,826 47.1%  
From Financial Activity Rs m-298-10,157 2.9%  
Net Cashflow Rs m501-2,615 -19.2%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 37.8 5.3%  
FIIs % 1.6 8.6 18.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 25.9 83.0%  
Shareholders   41,647 56,241 74.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Volatility, RBI Policy Meet Takeaways, and Top Cues in Focus Today(Pre-Open)

It was a volatile day for India share markets on Friday. The benchmark indices opened higher but turned volatile.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Mar 27, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS